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Abstract
Background: Uvaria chamae (UC) and Olax subscorpioidea (OS) roots are included in traditional anti-cancer
remedies and some studies have identified their chemopreventive/chemotherapeutic potential. This study aimed to
identify some cellular/molecular mechanisms underlying such potential and the associated chemical constituents.
Methods: Effect on the viability of cancer cells was assessed using the Alamar Blue assay; ability to modulate
oxidative stress was assessed using the 2′,7′-dichlorofluorescein diacetate (DCFDA) assay; potential to modulate
Nuclear factor erythroid 2-related factor like-2 (Nrf2) activity was assessed in the AREc32 luciferase reporter cell line;
and anti-inflammatory effect was assessed using lipopolysaccharide-induced nitric oxide release model in the
RAW264.7 cells (Griess Assay). Chemical constituents were identified through liquid chromatography-mass
spectrometry (LC-MS).
Results: Extracts up to 100 μg/ml were non-toxic or mildly toxic to HeLa, AREc32, PC3 and A549 cells (IC50 >
200 μg/ml). Each extract reduced basal and peroxide-induced levels of reactive oxygen species (ROS) in HeLa cells.
OS and UC activated Nrf2, with UC producing nearly four-fold induction. Both extracts demonstrated anti-
inflammatory effects. Chamanetin, isochamanetin, isouvaretin, uvaricin I and other compounds were found in U.
chamae root extract.
Conclusion: As Nrf-2 induction, antioxidant and anti-inflammatory activities are closely linked with
chemoprevention and chemotherapy of cancers, the roles of these plants in traditional anti-cancer remedies are
further highlighted, as is their potential as sources of drug leads.
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Background
The incidence and prevalence of cancer in the devel-
oping world are on the rise [1, 2]. Factors such as
demographic changes and growing economies are
consequently shifting the disease burden in these re-
gions from infections to non-communicable diseases
[2, 3]. Unfortunately, there is an unmet need for ef-
fective and affordable approaches to the early detec-
tion, diagnosis, prevention and treatment of cancer in
these countries [4, 5].
A significant population in these countries, estimated
to be up to 80% in some, use herbal remedies as their
primary form of health care, even in cancer management
[6]. It has been established that natural products contain
numerous chemical entities which are pharmacologically
active and could act together to affect multiple biological
pathways, resulting in the potential efficacy of natural
drugs to treat complex pathologies such as cancer [7].
While many plants are employed in traditional medicine
as alternative approaches to western medicine in cancer
therapy in developing countries [8–11], there is a dearth
of robust scientific evidence of the mechanisms of action
and safety of many of these remedies.
Preparations from plants have been used as anticancer
remedies in regions of Nigeria. Olax subscorpioideae
Oliv. (Olacaceae) and Uvaria chamae P. Beauv. (Anno-
naceae) are included in decoctions used to treat various
cancer subtypes amongst the Ijebu tribe of Nigeria [11].
In that article, Olax subscorpioidea was reported to have
been cited by 21% of the traditional healers surveyed.
Much earlier, Soladoye et al. [9] had reported the wide-
spread use of U. chamae and O. subscorpioidea as com-
ponents of several anticancer remedies by traditional
healers in South-West Nigeria.
Our previous studies sought to clarify whether or not
there are scientific bases for the use of some of these
remedies. Our results demonstrated the analgesic and
anti-inflammatory activities of these two plants' extracts
in animal models [12]. We also showed that these plants
possess free radical-scavenging activities, the ability to
protect against induced oxidative stress in rodent
models, as well as mito-depressive and DNA-damaging
properties [13]. These results have so far demonstrated
the possible chemopreventive and chemotherapeutic po-
tentials of these plants, which may explain their role in
traditional remedies that employ them in the therapy of
cancers.
To further understand the mechanistic underpinnings
of the effects observed in animal models, the study re-
ported herein employed validated in vitro (cell-based)
systems to investigate these plant extracts for their ef-
fects on cell viability, oxidative stress and inflammation.
We first explored the cytotoxicity, or otherwise, of the
extracts, using human cervical adenocarcinoma cells
(HeLa), modified human breast cancer cells (AREc32,
which is the MCF-7 cell line stably transfected with the
antioxidant response element (ARE) reporter plasmid),
human prostate cancer cells (PC3) and human lung can-
cer cells (A549). We then assessed their anti-oxidant ac-
tivities by examining their ability to reduce or prevent
intracellular build-up of reactive oxygen species (ROS)
and to induce Nrf-2 activation. Their anti-inflammatory
activities were examined in the lipopolysaccharide
(LPS)-induced nitric oxide model using RAW264.7 mur-
ine macrophages. Chemical profiling of the extracts was
then undertaken using Liquid Chromatography-Mass
Spectrometry (LC-MS) to reveal their constituents. Our
findings provide significant insights into the biological
effects of extracts from these plants, the mechanisms
underlying the effects, and the compounds that could be
responsible for the effects. The work provides some ra-
tionale for the inclusion of components of these plants
in documented traditional anti-cancer remedies and
identifies potential anti-cancer agents.
Methods
Plant materials
Fresh roots of Uvaria chamae P. Beauv. (Annonaceae)
and roots of Olax subscorpioidea Oliv. (Olacaceae) were
obtained from Mushin market, Mushin, Lagos State,
Nigeria. They were identified and authenticated by Mr.
T.K. Odewo, a forestry expert in the Department of Bot-
any Herbarium, Faculty of Science, University of Lagos,
Akoka, Lagos, Nigeria. Voucher specimens (U. chamae,
voucher number 3626; O. subscorpioidea, voucher num-
ber 5577) were deposited in the Herbarium of the
Department.
Extraction
Details of the extraction process have been previously
reported [13]. In brief, the freshly harvested plant parts
were washed and chopped into smaller pieces and dried
in open air for 2 weeks and thereafter ground to powder.
Hydroethanolic extracts were prepared by soaking pow-
dered plant parts in 90% ethanol for 72 h and thereafter
filtered using Whatman filter paper (~ 9 cm). Each fil-
trate was poured into drying trays and evaporated to
dryness in an oven at 40 °C. The dried extracts were re-
covered and stored in clean sample bottles [13].
Chemicals and assay and culture reagents and materials
Chemicals, including MTT, were from Sigma-Aldrich
(UK), except where otherwise stated. The Griess Assay
reagent (Cat. No. G2930) and the luciferase assay system
(Cat. No. E4530) were from Promega (UK), while the
DCFDA reagent (Cat. No. ab113851) was from Abcam,
UK. Lipopolysaccharide (LPS), S-form, made from S.
typhimurium (Cat. No. IAX-100-011-M001), was from
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Caltag Medsystems (UK), while IFN-γ (Cat. No. 485-MI)
was from Tocris Bioscience (Biotechne/R&D Systems),
UK. Cell culture reagents (basal medium (DMEM),
Foetal Calf Serum, L-glutamine, antibiotic-antimycotic
(anti-anti) solution (Penicillin/Streptomycin/Amphoteri-
cin B), recombinant trypsin solution (TrypLE)) and Ala-
mar blue (Cat. No. DAL1100) were from Thermo Fisher
Scientific, while DMEM and G-418 for the AREc32 cells
were from Biosera (through Labtech International Ltd.,
UK). Solvents were from Thermo Fisher, of analytical
grade and used without any purification. Specialised
black and white 96-well flat-bottom plates were from
Greiner Bio-One (UK).
Cell culture
All cells were grown as adherent monolayer cultures in
T75 tissue culture flasks and maintained at 37 °C in a
humidified atmosphere of 5% CO2 and 95% air. HeLa
cells (immortalised human cervical cell line); PC3 cells
(human prostate cancer cell line) and A549 (human al-
veolar basal epithelial adenocarcinoma cell line) were
cultured in Dulbecco’s Modified Eagle Medium (DMEM,
with 4.5 g/L D-glucose) supplemented with 10% Foetal
Calf Serum (FCS), 1% L-Glutamine (2 mM), 1% Non-
Essential Amino Acids (NEAA) and 1% anti-anti solu-
tion. The MCF-7 AREc32 cell line was cultured in
DMEM supplemented with 10% FCS, L-glutamine (2
mM), anti-anti solution and geneticin (G418; 0.8 mg/ml).
The RAW 264.7 cell line (murine macrophages) was cul-
tured in DMEM supplemented with 10% FCS and 1% L-
glutamine (2 mM) but without antibiotics.
All cells were originally from the European Collection
of Authenticated Cell Cultures (ECACC), Salisbury, UK,
except AREc32 cells, which were a kind gift to Dr. Ken-
neth Ritchie from Professor Roland Wolf (University of
Dundee, UK), whose lab created the cell line [14].
Cells were detached from flasks through trypsinisation
with recombinant trypsin (TrypLE), except the
RAW264.7 cells that were detached mechanically
through the use of cell scrapers. Cell density was deter-
mined through haemocytometer-assisted counting [15].
Cell viability assays
Alamar blue (AB) assay
HeLa, PC3, A549 and AREc32 cells were cultured in
their respective media until they reached approximately
80% confluency before using them for the cytotoxicity
assay. Cells were seeded into black, microclear 96-well
plates at 1 × 105 cells/ml (100 μl/well) and incubated for
24 h at 37 °C and 5% CO2 to allow the cells to attach.
After 24 h, the medium was discarded and the wells
thereafter treated with 100 μl of the different concentra-
tions of extracts prepared in medium. A set of untreated
control wells was included in each plate, as well as cells
treated with the positive control doxorubicin at up to
20 μM. Following incubation with extracts or doxorubi-
cin for 24 h, 10 μl of Alamar blue solution was added to
each well (10% v/v). Following 3 h incubation, fluores-
cence was quantified at the respective excitation and
emission wavelengths of 530 nm and 600 nm using a mi-
croplate reader (CLARIOstar Microplate Reader, BMG
LABTECH, UK). Each treatment was run in triplicate
and each experiment was repeated three times. The per-
centage cell viability was determined relative to the
vehicle-treated control cells [16]:
%Cell Viability ¼ F1=F0½   100
Where F0 is the mean fluorescence intensity of the
triplicate set of vehicle-treated control wells and F1 is
the mean fluorescence intensity of each triplicate set of
compound- or extract-treated wells.
Bright-field imaging
Changes to cell morphology as induced by the various
treatments were monitored on an Olympus CKX41
microscope fitted with an Olympus DP71 U-TVIX-2
camera. Images were acquired using the Olympus cell-
Sens entry software.
MTT assay
RAW264.7 cells were cultured and seeded in 96-well
plates for MTT cytotoxicity assay [16] to evaluate the
potential of each plant extract (5–50 μg/ml) and of the
anti-inflammatory agents prednisolone (5–50 μM) and
diclofenac (5–50 μM) to alter cell viability. Cells were
seeded into opaque, microclear, 96-well plates at a dens-
ity of 2.5 × 105 cells/well (100 μl/well) and left for 24 h in
the incubator at 37 °C and 5% CO2 to allow the cells to
attach. After 24 h, the growth medium in each well was
aspirated and the wells were treated with 100 μl of the
different concentrations of extracts or standards pre-
pared in growth medium. Following incubation for 24 h,
10 μl of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide, 5 mg/ml in PBS) was added to each
well. After 3 h incubation at 37 °C, the entire content of
each well was discarded and 100 μl of DMSO was added.
The absorbance at 570 nm was determined with a mi-
croplate reader (CLARIOstar Microplate Reader, BMG
Labtech, UK). Each experiment was repeated three
times, with three replicates for each treatment in each
experiment. The percentage cell viability was determined
as percentage of control cells.
%Cell Viability = [A1/A0] x 100
Where A0 is the mean absorbance of the vehicle-
treated (control) wells and A1 is the mean absorbance
of each triplicate set of extract- or positive control-
treated wells.
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Assessment of induction of reactive oxygen species (ROS)
This was done using the DCFDA Cellular ROS Detec-
tion Assay Kit. HeLa cells were seeded into a black, clear
bottom 96-well microplate at 2.5 × 105 cells/ml (25,000
cells/well at 100 μl/well). The cells were incubated at
37 °C in a humidified atmosphere of 5% CO2 and 95%
air and allowed to adhere overnight. The medium was
thereafter aspirated from each well, followed by rinsing
with the buffer provided in the assay kit. The buffer was
aspirated and the cells stained by adding 100 μl of a
25 μM DCFDA solution (diluted from a 20 mM stock).
Stained cells were incubated for 45 min at 37 °C in the
dark. After 45 min, DCFDA solution was removed and
the cultures were rinsed with the buffer. The rinse buffer
was then aspirated and replaced with 100 μl each of
plant extract (5, 25, 50, 100 μg/ml), H2O2 (10, 50,
200 μM) and ascorbic acid (AA) (50, 25, 50, 100 μM),
each in duplicate. Ascorbic acid is an antioxidant and so
was used as a positive control. Fluorescence (Ex/Em =
485/535 nm) of the wells was measured (CLARIOstar
Microplate Reader, BMG Labtech, UK) at 3 and 24 h fol-
lowing treatment. Background wells (untreated or
diluent-treated stained and unstained cells) as well as
blank wells (medium only) were included in each experi-
ment. Each experiment was repeated three times. Blank
readings were subtracted from all measurements and
fold change determined by setting the mean fluorescence
value for diluent-treated, stained, control cells to unity
and normalising every other mean fluorescence value to
it. This assay procedure was to determine whether each
of the tested extracts or compounds could modulate, on
its own, basal intracellular ROS.
The ability of each extract or ascorbic acid to modu-
late the increase in intracellular ROS induced by the oxi-
dative stressor hydrogen peroxide was also examined.
HeLa cells were grown and treated as described above.
Following aspiration of rinse buffer post-DCFDA stain-
ing, 50 μl of each plant extract (10, 50, 100, 200 μg/ml)
or AA (10, 50, 100, 200 μM) was added to individual
wells in duplicate, followed by 50 μl of 100 μM H2O2,
with an appropriate negative control and a peroxide
baseline included. The 1:1 (test agent: peroxide) volume
additions reduced the final concentration in each well to
half of the value indicated earlier in the paragraph.
Fluorescence measurements and data analyses were
done as described in the preceding paragraph.
Nrf2/ARE activation assay
The ability of the extracts to induce Nuclear factor
erythroid 2 (NF-E2)-related factor like-2 (Nrf2) activity
was determined in a luciferase reporter assay by using
the AREc32 cells (stable human mammary MCF-7-
derived reporter cell line with a luciferase reporter gene
construct that is under the control of the rat
Glutathione-S-Transferase (Gsta2) Antioxidant Response
Element (ARE) promoter, with eight copies of the ARE
in the promoter region [14]). The transcriptional regula-
tory element ARE is involved in the activation of genes
that code for a number of antioxidant proteins and en-
zymes that are protective against oxidative insults. The
induction of the genes is controlled by the transcription
factor Nrf-2, whose activity is usually repressed by the
inhibitory factor Kelch-like ECH associated protein 1
(Keap1) that facilitates its degradation, while electro-
philic agents prevent Keap1 from targeting Nrf2 for deg-
radation [14]. The AREc32 cell line is, therefore, used to
examine whether an anti-cancer drug or drug candidate
can induce ARE-driven gene expression, as induction of
ARE causes luciferase activity.
AREc32 cells were seeded into 96-well plates at a
density of 1.2 × 104 cells per well. After 24 h, the
medium was discarded and 100 μl of medium containing
each plant extract was added at a range of concentra-
tions into receiving wells. Then, after another 24 h of in-
cubation, medium was discarded, cells were washed with
phosphate-buffered saline (PBS) and 20 μl of luciferase
lysis buffer was added to each well, followed by a freeze-
thaw cycle to achieve complete lysis. The cell lysate was
then aspirated and dispensed into a white 96-well
plate. 100 μl of a luciferase reporter substrate was then
added to each well and luminescence measured (CLAR-
IOstar Microplate Reader, BMG Labtech, UK) immedi-
ately. The level of luciferase activity for each treatment
was compared to the basal level of luciferase activity in
control cells and presented as a fold increase. Tert-butyl-
hydroquinone (tBHQ; 25 μM) served as positive control.
Each experiment was repeated three times, with three
replicates in each experiment.
Inhibition of nitric oxide (NO) production (Griess assay)
Following MTT assay and confirmation of the non-
toxicity of the tested concentrations, RAW 264.7 cells
were seeded into 96-well opaque plates at a density of
2.5 × 105 cells/well; after 24 h of incubation, the culture
medium was replaced with 90 μl of medium containing
different concentrations of extracts (for final concentra-
tions of 5, 10, 25, 50 μg/ml), diclofenac or prednisolone
(for final concentrations of 5, 10, 25, 50 μM). Following
1 h of incubation, 10 μl of 10 μg/ml LPS was added to
the wells containing the concentrations of the extracts
or positive control compounds (prednisolone and diclo-
fenac), as well as to the vehicle-treated wells (negative
controls without LPS or extract/compound were also in-
cluded). The final concentration of LPS to which cells
were exposed was 1 μg/ml. The cells were cultured for a
further 24 h, after which nitric oxide (NO) levels were
assessed by nitrite quantification as previously described
[17] using Promega’s Griess Reagent System. Briefly,
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experimental samples (50 μl supernatant from the wells)
as well as nitrite concentration standards prepared from
the supplied nitrite stock solution were incubated in the
dark, at room temperature, with 50 μl of suphanilamide
(1% in 5% H3PO4). After 10 min of incubation, 50 μl of
napthylethylenediamine (0.1% in distilled H2O) was
added and a further 10 min incubation was carried out
in the dark at room temperature. Absorbance was read
at 550 nm on a microplate reader (CLARIOstar Micro-
plate Reader, BMG Labtech, UK). Each experiment was
repeated three times, with each treatment assessed in
triplicate in each experiment. The nitrite concentration
was determined by comparison to a nitrite standard ref-
erence curve.
The ability of the extracts to inhibit NO production
following LPS stimulation potentiated by Interferon
gamma (IFNγ) was also investigated. RAW 264.7 cells
were seeded into 96-well opaque plates at a density of
2.5 × 105 cells/well; after 24 h of incubation, the culture
medium was replaced with 80 μl medium containing dif-
ferent concentrations of extracts (final concentrations of
5, 10, 25, 50 μg/ml), diclofenac or prednisolone (final
concentrations of 5, 10, 25, 50 μM). Diclofenac and
prednisolone are anti-inflammatory agents and so were
used as positive controls. Following 1 h of incubation,
10 μl of 1 μg/ml LPS was added to the wells, followed by
10 μl of 50 ng/ml IFNγ. The final concentrations of LPS
and IFNγ were 0.1 μg/ml and 5 ng/ml, respectively, and
negative controls were included. Cells were cultured for
a further 24 h, after which nitric oxide (NO) levels were
assessed by nitrite quantification as described earlier.
Liquid chromatography-mass spectrometry (LC-MS)
analyses
Analytical high-pressure liquid chromatography (HPLC)
experiments were performed on a Thermo Scientific
UPLC Dionex Ultimate 3000 series (Thermo Scientific,
UK) equipped with a binary pump, an autosampler, a
column chamber, a degasser and a UV/DAD detector.
Extracts prepared in methanol were analysed using a
Thermo Scientific Hypersil GOLD (150 × 4.6 mm, 5 μm;
Runcorn, UK) C18 column. The flow rate was set at 1
ml/min; solvent gradients of 50–100% MeOH over 30
min and 15–90% acetonitrile (ACN) over 30 min were
used to ensure optimal peak separations for UC and OS,
respectively. The column temperature was set at 25 °C.
The chromatogram for each extract was acquired at 280
nm.
The LC analysis was performed using a Waters 2695
Separation Module (Alliance) system (Milford, MA,
USA) coupled to a Waters 2487 Dual Absorbance De-
tector. Separation of compounds was performed on a
Thermo Scientific Hypersil GOLD (150 × 4.6 mm, 5 μm;
Runcorn, UK) C18 column using a linear gradient of 50–
100% MeOH over 30min and 15–90% ACN over 30
min, for UC and OS, respectively. Injection volume was
25 μl; flow rate was 1 ml/min. Mass spectra were ac-
quired using a Waters Micromass LCT Premier Mass
spectrometer (Milford, MA, USA) with an electrospray
interface in the positive mode (ESI+), and an ion spray
of 3 kV was used; sample cone voltage was set at 30 V;
mass (m/z) scan was set within the range of 100–1500.
Data acquisition and analysis were performed with Mas-
sLynx software (Waters, Milford, MA, USA).
Statistical analyses
All data are expressed as mean ± SEM. In order to assess
the statistical significance of the differences between
means, one-way analysis of variance (ANOVA) was con-
ducted, followed by Dunnett/Tukey multiple compari-
sons post-hoc test, as applicable. GraphPad Prism® 6
(GraphPad Software Inc., CA, USA) was used to accom-
plish statistical tests. Values of p < 0.05 were considered
statistically significant.
Results
Effects of extracts on cell viability
It was important to identify for the extracts both their
non-toxic range and toxic range of concentrations in
order to be able to appropriately design subsequent as-
says and interpret their data. The effect of a substance
on cell viability depends on the type of cell used, so we
explored a range of human cancer cell lines grown as
monolayer cultures: HeLa (cervical adenocarcinoma cell
line); AREc32 (a variant of the human mammary tumour
cell line MCF-7); A549 (alveolar basal epithelium adeno-
carcinoma cell line); and PC3 (prostate cancer cell line).
The cultures were treated with the concentrations of
each extract for 24 h, consistent with the duration of the
assays that the cells were to be subsequently used for.
Following treatments, the Alamar Blue reagent was used
to quantify changes to viability, complemented with
microscopic monitoring and capture of any associated
morphological changes. The anti-cancer drug doxorubi-
cin was included as a positive control. The effects of the
extracts and doxorubicin on the viability of HeLa and
AREc32 cells are shown in Fig. 1, while their effects on
PC3 and A549 cells are shown in Table 1. We first dem-
onstrated that the viability of each of the cell types could
be impaired through exposure to a known toxic agent
(doxorubicin), as doxorubicin reduced their viability in a
concentration-dependent manner, and the effects at
higher doxorubicin concentrations were significant.
In HeLa cells (Fig. 1), higher concentrations of OS and
UC reduced cell viability (most of them mildly), but the
IC50 values were greater than 200 μg/ml. The extracts
did not affect the viability of the AREc32 (MCF-7) cells
(IC50 > 500 μg/ml). In the A549 cells, even though some
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toxicity of the extracts began to be observed at relatively
low concentrations, the IC50 for each of the extracts was
greater than 250 μg/ml (Table 1). In the PC3 cells, sig-
nificant toxicity only occurred at 500 μg/ml for OS
(IC50 > 300 μg/ml) and from 200 μg/ml for UC (IC50 >
250 μg/ml) (Table 1). The morphological changes ob-
served following the treatments were consistent with the
viability changes. Photomicrographs of control cultures
and cultures of non-toxic or mildly toxic treatments re-
vealed confluent cells in a healthy organisation, while
cultures of overtly toxic treatments, exemplified by the
highest tested concentration (20 μM) of the standard,
doxorubicin (which elicited concentration-dependent
toxicity), revealed loss of confluency and thus of cell-cell
contacts, with some or most of the remaining cells
appearing rounded and shrunken (Fig. 2).
Using HeLa cells, we investigated whether a longer
treatment duration (48 h) could induce more significant
cytotoxicity. However, there were no differences between
the viability values obtained following 24 h treatments
with each extract and those obtained following 48 h
treatments (Figure S1 – supplementary data).
Fig. 1 Cell viability (%) (Alamar blue assay) in HeLa cells and AREc32 (MCF-7) cells following 24 h exposure to O. subscorpioidea, U. chamae and
doxorubicin. Each bar represents mean ± SEM (n = 3); *p < 0.05, αp < 0.01, βp < 0.001, γp < 0.0001 vs. control using one-way ANOVA followed by
Dunnett’s post hoc multiple-comparisons test
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Extracts reduced basal and hydrogen peroxide-induced
intracellular levels of ROS
OS and UC significantly reduced, at some or all of the
concentrations, basal intracellular ROS levels in HeLa
cells at 3 and 24 h, whereas ascorbic acid did not affect
the basal ROS levels (Fig. 3). H2O2 caused
concentration-dependent elevations of intracellular ROS
levels, which were significant at 50 μM and 200 μM, with
the latter producing nearly a 10-fold increase compared
to the negative control (Fig. 3).
The ability of each extract to inhibit peroxide-induced
elevation of intracellular ROS was then investigated. OS,
UC and ascorbic acid each attenuated the elevation of
intracellular ROS induced by hydrogen peroxide (10 μM)
(Fig. 4). The effects of OS on the 3.5-fold increase in
ROS induced by peroxide were clearly concentration-
dependent, and significant at 50 μg/ml and 100 μg/ml for
both time points, and at the 24 h time point its 100 μg/
ml completely inhibited the effect of peroxide. The ef-
fects of UC were only significant from 25 μM at the 24 h
time point. Ascorbic acid produced significant effects
only at the 3 h time point.
OS and UC induce Nrf2/ARE activation
The Nrf2-ARE signalling pathway is a key endogenous
cellular defence system against oxidative stress and some
Table 1 Percentage viability values for A549 and PC3 cells obtained in Alamar blue assay following 24 h exposure to O.





O. subscorpioidea U. chamae Doxorubicin
Conc.
(μM)
A549 PC3A549 PC3 A549 PC3
5 97.10 ± 1.24 97.46 ± 3.75 97.29 ± 1.50 92.55 ± 4.72 0.16 79.09 ± 11.39 91.90 ± 5.69
10 91.93 ± 1.67 93.77 ± 3.41 102.75 ± 3.33 93.25 ± 4.16 0.31 70.57 ± 9.02 83.34 ± 9.64
15 76.15 ± 1.47* 93.32 ± 1.85 104.67 ± 6.32 92.76 ± 4.77 0.63 66.76 ± 8.39* 83.97 ± 12.27
25 66.95 ± 2.25* 87.40 ± 4.62 102.61 ± 5.24 92.84 ± 7.03 1.25 62.98 ± 7.42* 76.50 ± 8.14
50 64.25 ± 3.43* 84.29 ± 5.62 105.88 ± 1.90 88.00 ± 5.15 2.5 60.04 ± 7.23* 68.52 ± 2.02*
75 61.17 ± 3.89* 81.30 ± 6.63 95.21 ± 6.59 86.93 ± 4.72 5 58.87 ± 8.34α 58.08 ± 0.20α
100 59.17 ± 4.40* 82.51 ± 6.08 92.77 ± 10.21 83.05 ± 4.31 10 56.25 ± 8.43α 57.23 ± 2.03β
200 61.30 ± 3.81* 82.87 ± 9.09 53.08 ± 7.58γ 56.91 ± 5.08γ 20 52.08 ± 7.47α 54.01 ± 1.15β
500 10.13 ± 0.62γ 20.36 ± 5.27γ 22.50 ± 10.02γ 21.04 ± 4.16γ
IC50 ≈ 270 ≈ 304 ≈ 274 ≈ 273 > 20 > 20
Cell viability (%) of A549 and PC3 cells following 24 h exposure of the cells to varying concentrations of test agents as measured by the Alamar blue assay. Values
are presented as mean ± SEM (n = 3). *p < 0.05, αp < 0.01, βp < 0.001, γp < 0.0001 vs. control (100% viability) using one-way ANOVA followed by Dunnett’s post hoc
multiple-comparisons test.
Fig. 2 Brightfield photomicrographs showing the non-toxic effects of OS and UC (up to 100 μg/ml) and the toxic effect of the positive control
doxorubicin on the morphology of HeLa cells. Cultures were exposed to each agent for 24 h. Scale bar = 100 μm
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antioxidants are known to act by activating this system
[18]. We, therefore, tested the ability of each extract to
activate the Nrf-ARE pathway. This was done using the
stable AREc32 luciferase reporter cell line, derived from
the human mammary MCF-7 cell line, with its luciferase
reporter gene construct under the control of the rat
Glutathione-S-Transferase (Gsta2) Antioxidant Response
Element (ARE) promoter [14]. The extract concentra-
tions used had been determined to be non-toxic to the
AREc32 cells, evidenced by their not reducing viability
for any more than 10% in the Alamar Blue viability
assay. As shown in Fig. 5, the antioxidant Nrf2 activator
tert-butylhydroquinone (tBHQ) (25 μM), used as a posi-
tive control, potently induced a significant, almost ten-
fold, increase in Nrf2 activity compared to the negative
(unstimulated) control. OS significantly activated Nrf2 at
15 and 25 μg/ml (Fig. 5A). Remarkably, UC produced a
significant and concentration-dependent activation of
Nrf2, an effect that was significant even at a concentra-
tion as low as 2.5 μg/ml (P < 0.01), with the highest
concentration tested (200 μg/ml) producing a more than
3-fold activation (P < 0.0001) of Nrf2 activity (Fig. 5B).
Extracts of OS and UC inhibited lipopolysaccharide (LPS)-
induced nitric oxide (NO) production
Figure 6 shows the results of the MTT assay evaluating
the potential effects of the extracts, diclofenac and pred-
nisolone on RAW264.7 cell viability. The results demon-
strate the non-toxic effects of the extracts and chemicals
on the cells at the test concentrations.
Figure 7 summarises the results of the subsequent
assay evaluating the inhibition of NO production in
RAW264.7 cells by the study plants at the concentra-
tions confirmed to be non-toxic to the cells. LPS (1 μg/
ml) significantly increased the levels of the pro-
inflammatory mediator NO compared to the negative
control (P < 0.001). OS and UC were significant inhibi-
tors of the LPS-induced NO. The effects of these ex-
tracts were similar to that observed with the positive
control prednisolone, where NO levels were restored to
Fig. 3 Intracellular Reactive Oxygen Species (ROS) levels presented as fold increases in fluorescence (Relative Fluorescence Unit, RFU) relative to
the negative control, following 3 h and 24 h exposures of HeLa cells to extracts of O. subscorpioidea (A), U. chamae (B), and to Ascorbic acid (C)
and Hydrogen peroxide (D). Each bar represents Mean ± SEM (n = 3); *p < 0.05, αp < 0.01, βp < 0.001, γp < 0.0001 versus negative control (nil
concentration) using one-way ANOVA followed by Dunnett’s post hoc multiple-comparisons test
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Fig. 4 Intracellular Reactive Oxygen Species (ROS) levels as fold increases in fluorescence (Relative Fluorescence Unit, RFU) relative to the negative
control (indicated as “C”), following 3 h and 24 h exposures of HeLa cells to extracts of O. subscorpioidea (A), U. chamae (B), and to Ascorbic acid
(C), each in the presence of Hydrogen peroxide (50 μM). Each bar represents Mean ± SEM (n = 3); ap < 0.05, bp < 0.01 versus vehicle (negative)
control (indicated as “C”); *p < 0.05, αp < 0.01 versus peroxide only-treated control using one-way ANOVA followed by Dunnett’s post hoc
multiple-comparisons test
Fig. 5 Nrf2 activation following exposure of AREc32 luciferase reporter cells to extracts of O. subscorpioidea (A) and U. chamae (B). Each bar
represents Mean ± SEM (n = 3); C1 denotes negative (unstimulated) control, while C2 denotes positive control, which is the antioxidant Nrf2
activator tert-butylhydroquinone (tBHQ) at 25 μM; *p < 0.05, αp < 0.01, γp < 0.0001 versus negative control (C1) using one-way ANOVA followed by
Dunnett’s post hoc multiple-comparisons test
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control levels following treatment with the higher con-
centrations of the agents.
However, the linear correlation between absorbance
values and nitrite levels as shown in Fig. 7A (r2 = 0.9999)
suggests that the levels of nitric oxide (indicated by ni-
trite levels) induced by LPS alone (absorbance of about
0.08, correlated to very low nitrite levels) were quite low.
We, therefore, potentiated LPS-induced NO release with
the addition of IFN-γ at 5 μg/ml [19] (the concentration
of LPS was reduced 10-fold to 0.1 μg/ml) (Fig. 8). Fol-
lowing this potentiation, NO levels induced by IFN-γ-
potentiated LPS were at least 3-fold higher than those
induced by LPS alone, with the absorbance values for
the potentiated effect correlating with average nitrite
concentrations of nearly 40 μM. Each extract produced
significant, concentration-dependent inhibition of NO
release following potentiated LPS stimulation, which was
significant at 50 μg/ml for OS and 25 and 50 μg/ml for
UC, although neither of them restored NO levels to that
of the control. The standards prednisolone and diclofe-
nac showed no significant effects (Fig. 8).
Chromatographic and mass spectrometric analyses
Our approach to medicinal plants research focusing on
drug discovery recognises and addresses the need to
identify chemical constituents in extracts that might be
responsible for their observed biological activities. We,
therefore, employed chromatographic and mass spectro-
metric analyses (coupled) to resolve the constituents of
the two extracts investigated. The LC-MS chromato-
grams for the OS and UC extracts are shown in Figs. 9
and 10, respectively. Analysis of the ion spectra data (m/
z for each peak; MS) from the chromatogram of the ex-
tract from the root of U. chamae revealed the possible
presence of bullanin, bullatencin, chamanetin, desacety-
luvaricin, dichamanetin, diuvaretin, isochamanetin, isou-
varetin (chamuvarin), neoannonin, squamocin, uvaretin,
uvaricin I and uvaricin II (Table 2), the structures of
Fig. 6 Cell viability (%) of RAW264.7 murine macrophage cells following 24 h exposure to extracts of O. subscorpioidea (A), U. chamae (B) and to
Diclofenac, (C) and Prednisolone (D), as quantified using the MTT assay. Each bar represents mean ± SEM (n = 3); *p < 0.05, αp < 0.01 vs. control
using one-way ANOVA followed by Dunnett’s post hoc multiple-comparisons test
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Fig. 7 Nitric oxide (NO) release following 24 h stimulation of RAW264.7 murine macrophage cells with lipopolysaccharide (LPS) in the absence or
presence of extracts of O. subscorpioidea (B), U. chamae (C), and of Prednisolone (D) and Diclofenac (E). A describes the standard nitrite curve
obtained. Each bar represents Mean ± SEM (n = 3); *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle-treated control (C); ap < 0.05, αp < 0.01, βp <
0.001 versus LPS-treated cultures using one-way ANOVA followed by Dunnett’s post hoc multiple-comparisons test
Fig. 8 Nitric oxide (NO) release following 24 h stimulation of RAW264.7 murine macrophage cells with LPS+ IFN-γ in the absence and presence of
extracts of O. subscorpioidea (B), U. chamae (C), and of Prednisolone (D) and Diclofenac (E). A describes the standard nitrite curve obtained. Each
bar represents Mean ± SEM (n = 3); ap < 0.001 versus vehicle-treated control; dp < 0.001 versus LPS-treated control; *p < 0.05, αp < 0.01, γp < 0.001
versus LPS+ IFN-γ-treated cultures using one-way ANOVA followed by Dunnett’s post hoc multiple-comparisons test
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Fig. 9 Chromatographic data for O. subscorpioidea root extract. A HPLC-DAD, B LC-MS
Fig. 10 Chromatographic data of U. chamae root extract. A HPLC-DAD, B LC-MS
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some of which are shown in Fig. 11. Ion spectra data
from MS chromatogram of O. subscorpioidea did not
match any previously reported compounds in the plant.
Discussion
This study provides a key evidence base for the use of
two plants, Uvaria chamae and Olax subscorpioidea, in
the traditional treatment of cancers, and identifies them
as potential sources of anti-cancer compounds. The
findings are consistent with the exceptional success in
identifying anti-cancer principles or their precursors
from medicinal plants, as more than 60% of clinically-
approved anticancer drugs are derivatives of medicinal
plants [27]. The importance, relevance and timeliness of
this work could be further appreciated upon consider-
ation that 80% of the world’s population depend on trad-
itional medicines to date [28]. Oxidative stress and
inflammation, both of which mechanisms are unequivo-
cally linked to the initiation, promotion and progression
of cancers, were the focus of this work, and we demon-
strated that the plants were able to combat these patho-
mechanisms, although to varying degrees.
Assessment of viability confirmed that the extracts at
the concentrations used in the subsequent antioxidant
assays (in HeLa and AREc32 cells) and anti-
inflammatory assays (in RAW264.7 cells) were generally
non-cytotoxic, and it is possible that the profile of mild,
non-concentration-dependent toxicity seen at any
Table 2 LC-MS identification of compounds in U. chamae roots
Retention Time (min) m/z Possible matcha References
1 14.743 363.1907 Chamanetin, Isochamanetin [20]
2 15.760 385.1786 Chamanetin, Isochamanetin [20]




4 20.246 401.2128 Isouvaretin (Chamuvarin) [21]
5 20.630 491.2543 Dichamanetin [20]
6 22.531 613.3497 Bullatencin [23]
7 23.031 507.2805 Diuvaretin [22]
8 25.949 645.5989 Squamocin [24]
9 27.700 601.5641 Neoannonin [25]
10 28.701 629.6179 Uvaricin I/II [26]
11 29.134 629.6061 Desacetyluvaricin [24]
aThe compounds were identified by comparing m/z data (ion mass) of the sample with the values reported in the literature
Fig. 11 Structure of constituents of Uvaria chamae root extract identified by LC-MS
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extract concentration below 100 μg/ml could have been
a result of some assay artefacts, a view corroborated by a
correlation of the viability data with the accompanying
level of morphological damage as shown by the photo-
micrographs in which extract concentrations up to
100 μg/ml did not reveal any discernible morphological
damage, while 200 μg/ml or higher for some extracts
demonstrated overt toxicity. We were, therefore, able to
establish that lower concentrations of the extracts could
be useful as adjunct chemoprevention and/or chemo-
therapy, while the effects of higher concentrations were
consistent with potential use in cytotoxicity-dependent
chemotherapy. However, it is important to assess in the
future whether the lower concentrations that were not
directly cytotoxic in our investigation could induce dir-
ect toxicity if the cancer cells were exposed to them for
a longer duration.
The extracts demonstrated potent antioxidant effects
by directly combatting the levels of ROS induced by
hydrogen peroxide and also by activating the cellular
Nrf2-ARE antioxidant defence system. Oxidative stress
contributes to the initiation, promotion and progression
of neoplasms [29]; reducing oxidative stress is thus im-
portant, especially in cancer prevention. Over the years,
phytochemicals have shown promising chemopreventive
effects in several cancer types as a result of their antioxi-
dant properties [30]. Documented in vitro and in vivo
data show that, in addition to preventing oxidative dam-
age, antioxidants may alter the intracellular redox state,
by which they enhance the effects of cytotoxic therapy.
Also, through this mechanism, they could selectively in-
hibit tumour cell growth [31]. Results from the current
study show that the two extracts produced significant re-
ductions in basal intracellular ROS levels in HeLa cells,
measured over a 24 h period. Hydrogen peroxide tra-
verses the cell membrane fairly rapidly, and its high
levels can cause oxidative damage to cells. Also, hydro-
gen peroxide releases active oxygen species (highly react-
ive hydroxyl radical) through the Fenton reaction [32,
33]. The hydroxyl radical reacts with biological mole-
cules such as proteins and DNA and is also known to in-
duce lipid peroxidation through the removal of
hydrogen atoms from membrane lipids [34–36]. The ex-
tracts showed significant reduction of H2O2-induced
ROS levels measured over a 24 h period following initi-
ation of exposure. This result strongly corroborates our
previous study which demonstrated the in vivo antioxi-
dant activities of these extracts, particularly their ability
to prevent lipid peroxidation [13], which is a key conse-
quence of oxidative stress.
To better understand the mechanisms underlying the
antioxidant actions of the extracts, we explored the po-
tential involvement of the Nrf2-ARE signalling pathway,
a major cellular antioxidant defence system [14]. The
importance of Nrf2 activators was highlighted by the
studies of Lee Wattenberg and Paul Talalay, which dem-
onstrated in mouse models that phenolic antioxidants
prevented chemical carcinogenesis through the upregu-
lation of enzymes involved in metabolism [37, 38]. It
was later established that this effect was a result of the
activation of the NRF2 pathway [18]. Thus, inducers of
Nrf2 are considered important cancer chemopreventive
agents. Nrf2 is a regulatory transcription factor that in-
duces genes that play critical roles in oxidative and
xenobiotic stresses [39]. When cells are exposed to re-
active oxygen species (ROS), Nrf2 rapidly accumulates in
the nucleus and subsequently heterodimerises with
members of the small Maf protein family to act upon
Antioxidant Response Element (ARE) sequences as a
transcriptional activator [40, 41]. The ARE is found in
the promoter region of genes encoding detoxification
enzymes (e.g., Phase II enzymes) and other cytoprotec-
tive proteins [42]. The induction of enzymes, such as
glutathione S-transferase, NAD(P)H:quinone oxidore-
ductase, UDP-glucuronosyltransferase, aldehyde de-
hydrogenase, γ-glutamate cysteine ligase and glutathione
synthetase, helps in the deactivation of oxidative toxi-
cants before they cause damage to critical cellular mac-
romolecules [40].
In this study, we evaluated, using the AREc32 lucifer-
ase reporter cell line, the induction/activation of Nrf2-
ARE by the study plants. The AREc32 cell line is human
MCF-7 breast cancer cell line that was stably transfected
with a luciferase reporter gene construct under the con-
trol of eight copies of rat Gsta2 AREs in the promoter
region, and it is used to assess whether a molecule could
elicit antioxidant activity by inducing Nrf2 activation.
While OS induced Nrf2 activity at some concentrations,
the potent and concentration-dependent Nrf2-inducing
activity of UC was quite remarkable and deserves further
investigations into the role UC and its constituents may
play in the chemoprevention and treatment of diseases
where oxidative stress has been implicated.
However, recent studies have shown that the induction
of Nrf-2 could be a double-edged sword, thus warranting
caution. For example, evidence indicates that Nrf2 can
rewire metabolic programmes to promote cancer cell
growth and proliferation as well as promote chemo-
resistance and radio-resistance [43, 44]. Lau and col-
leagues showed a positive correlation between Nrf2
levels and resistance of cancer cell lines to cisplatin,
doxorubicin, and etoposide [45]. Wang and colleagues
also reported that tert-butylhydroquinone (tBHQ) pre-
treatment results in activation of Nrf2, which leads to
survival of neuroblastoma cells treated with cisplatin,
doxorubicin and etoposide [46]. While these data sug-
gest that the role of Nrf-2 in specific cancers would need
to be ascertained, the ability of the extracts to induce
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Nrf-2 activation as we have shown in this study lends
credence to their potential, as well as the potential of
their constituent compounds, to elicit beneficial effects
in the chemoprevention of cancers.
Inflammation and cancer were first linked as far back
as a century and a half ago when Virchow highlighted
the tendency for cancers to occur at sites of chronic in-
flammation [47]. Epidemiological investigations have
also shown that inflammatory diseases are frequently as-
sociated with increased risks of certain cancers [48]. Ni-
tric oxide (NO) and prostaglandins are important for
provoking and maintaining an inflammatory condition
[49], which is why we assessed the ability of the extracts
to lower excessive levels of NO, as an indicator of their
anti-inflammatory potential. The RAW264.7 murine
macrophage cell line used in our work is commonly
used to model macrophage-mediated inflammatory
events in vitro [50, 51]. To induce NO production, we
challenged the cells with lipopolysaccharide (LPS), as its
stimulation has been demonstrated to induce iNOS ex-
pression as well as to increase NO production and pros-
taglandin synthesis in RAW 264.7 cells [51–54]. A
similar effect of LPS was seen from our results (Fig. 7),
as NO levels (measured as nitrite levels) were increased
in RAW 264.7 cells following LPS stimulation. Treat-
ment of the cells with OS and UC, however, significantly
decreased NO production at all concentrations tested.
Due to relatively low levels of nitrite obtained follow-
ing stimulation with LPS alone, and in a bid to ensure
the effects we assessed were quite physiologically and
pathologically relevant, IFN-γ was used to potentiate the
NO-releasing action of LPS. This generated a much
higher level of nitrite than was obtained with LPS alone.
The two extracts each caused a decrease in the NO pro-
duction induced by stimulation of RAW 264.7 cells with
LPS/IFN-γ. The anti-inflammatory effects were con-
firmed not to be as a result of the cells dying following
the treatments, but are proposed to be through suppres-
sion of iNOS mRNA and protein expression in LPS-
induced RAW 264.7 cells.
While we identified the antioxidant and anti-
inflammatory effects of the extracts without evidence of
potent direct toxicity, we recognise the importance of in-
vestigating in the future longer-time treatments (e.g., 72
h or 96 h), on the basis that their antioxidant and anti-
inflammatory effects in cancer cells would be expected
to lead ultimately to the death of those cancer cells. It is
also important within this context to test in the future
for the ability of the extracts to selectively kill cancer
cells at concentrations and exposure durations at which
they do not affect the viability of normal cells.
LC-MS analysis of UC extract revealed the possible
presence of previously documented compounds. The C-
benzylated flavanones chamanetin, isochamanetin and
dichamanetin have been shown to be effective adjuvants
in antibiotic treatment of infections [55, 56]. The insecti-
cidal, larvicidal, antimalarial and fungicidal efficacies of
the compounds from Uvaria species (particularly cha-
manetin and dichamanetin) have also been reported [22,
57, 58]. While santalbic acid has been isolated from O.
subscorpioidea (OS) [59], we could not relate the m/z
data obtained for the OS extract with any documented
compounds from this plant species. A detailed study in
the future will assess the specific contributions of the
constituent compounds to the establishment of the bio-
logical effects observed in this study.
Conclusion
This study has demonstrated the Nrf-2-inducing, anti-
oxidant and anti-inflammatory effects of our study
plants in validated cell-based models. As these activities
are closely linked to the chemoprevention and chemo-
therapy of cancers, the work has expanded our under-
standing of the roles of these plant extracts in traditional
remedies that employ them in the therapy of cancers. It
has also pointed attention in the direction of these plants
for drug discovery purposes.
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